Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by N0taP00pon Jan 06, 2023 11:52am
210 Views
Post# 35207037

RE:RE:RE:RE:RE:RE:RE:RE:RE:January 9th warrants

RE:RE:RE:RE:RE:RE:RE:RE:RE:January 9th warrantsI may be one of the few voices here who don't like  these warrant extensions.  As opposed to being shareholder friendly, it could also be an indicator of potential delays and a lack of confidence in their own projected timelines. The tendency to ascribe only positive reasons for anything that smells fishy was a regular feature in my other Canadian investment that tanked.  Every delay was met with a hopeful cheer and a litany of reasons why it could be a good thing. Each exec hired -or leaving - was explained away as decisions made by wise men and women who knew what they were doing.  FDA submission was always around the corner, till it was not. Self-styled message board gurus churned out endless "data" and history lessons to convince everyone.  Always used to wonder why medical devices analysts never covered that company.  So excuse me for being a show-me skeptic.  I hold quite a bit of shares and I believe in the technology and the possibilities pointed out by many. My fear is always poor execution and  decisions that either cause constant delays or  dilute share price.  And the massive hole in awareness of this company.   I hope the next announcement is not another round of selling shares and warrants to raise money.  I want to see the clinical data submission as an NR. Was supposed to happen in Q4. 
<< Previous
Bullboard Posts
Next >>